Sodium hydrogen-S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913): Toxicity and bone marrow radioprotection

Oscar A. Mendiondo, Andrew M. Connor, Perry Grigsby

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Experiments have been carried out to compare the toxicity and radioprotective effect of sodium hydrogen-S-(3-amino-2-hy(iroxypropyl) phosphorothioate (WR-77913) with those of S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721). The drugs were given intraperitoneally to 12 week-old female BALB/c mice 30 minutes before whole body irradiation. Lethality at 30 days was the endpoint used. The drug LD 50 30 was 678 mg/kg for WR-2721 and 3574 mg/kg for WR-77913. The LD 50 30 for WR-77913 combined with 500 mg/kg of WR-2721 was 3328 mg/kg. The LD 50 30 for misonidazole was 380 mg/kg when given in combination with 500 mg/kg of WR-2721 and 801 mg/kg when combined with 2200 mg/kg of WR-77913. Protection of bone marrow by WR-77913 and WR-2721 was comparable at doses close to the maximum tolerable dose (MTD, drug dose lethal to 10% of the animals at 30 days), but W R-77913 gave better protection at 25% of the MTD. These characteristics of low toxicity, non-additive toxicity with WR-2721, less toxicity in combination with misonidazole and adequate bone marrow protection at 25`,0 of the MTD, make WR-77913 a protector worthy of further investigation.

Original languageEnglish
Pages (from-to)553-555
Number of pages3
JournalInternational journal of radiation oncology, biology, physics
Issue number3-4
StatePublished - 1982


  • Misonidazole
  • Radioprotectors
  • WR-2721
  • WR-77913


Dive into the research topics of 'Sodium hydrogen-S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913): Toxicity and bone marrow radioprotection'. Together they form a unique fingerprint.

Cite this